Form 4: BioCryst Pharmaceuticals Director, Nancy J. Hutson, Reports Stock and Option Grant

Nancy J. Hutson, a director at BioCryst Pharmaceuticals, reported the acquisition of restricted stock units and stock options on June 12, 2024, as part of the company's non-employee director compensation policy.

Summary

• On June 12, 2024, Nancy J. Hutson, a director at BioCryst Pharmaceuticals, acquired 6,820 shares of common stock and was granted options for 49,933 shares.
• The common stock was acquired through an automatic non-employee director grant of Restricted Stock Units (RSUs) under the company's Non-Employee Director Compensation Policy.
• These RSUs will vest on the first anniversary of the grant date.
• The stock options were also granted automatically under the same policy, with an exercise price of $6.30, exercisable from June 12, 2025, and expiring on June 12, 2034.
• Following these transactions, Ms. Hutson beneficially owns 93,638 shares of common stock and 49,933 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices, aligning director interests with shareholders.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule of the restricted stock units encourages long-term commitment from the director.

Industry Context

Director compensation through stock and options is a common practice in the pharmaceutical industry to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Granting stock options and restricted stock units to directors is a standard practice among publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation strategies to attract and retain qualified board members.
• The specific amounts and vesting schedules can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates